These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 25948622)

  • 1. Multiple sclerosis patient-derived CSF induces transcriptional changes in proliferating oligodendrocyte progenitors.
    Haines JD; Vidaurre OG; Zhang F; Riffo-Campos ÁL; Castillo J; Casanova B; Casaccia P; Lopez-Rodas G
    Mult Scler; 2015 Nov; 21(13):1655-69. PubMed ID: 25948622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid derived from progressive multiple sclerosis patients promotes neuronal and oligodendroglial differentiation of human neural precursor cells in vitro.
    Cristofanilli M; Cymring B; Lu A; Rosenthal H; Sadiq SA
    Neuroscience; 2013 Oct; 250():614-21. PubMed ID: 23876320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
    Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E
    J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis.
    Matsushita T; Tateishi T; Isobe N; Yonekawa T; Yamasaki R; Matsuse D; Murai H; Kira J
    PLoS One; 2013; 8(4):e61835. PubMed ID: 23637915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transglutaminase-6 is an autoantigen in progressive multiple sclerosis and is upregulated in reactive astrocytes.
    Cristofanilli M; Gratch D; Pagano B; McDermott K; Huang J; Jian J; Bates D; Sadiq SA
    Mult Scler; 2017 Nov; 23(13):1707-1715. PubMed ID: 28273770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased cerebrospinal fluid chitotriosidase index in patients with multiple sclerosis.
    Verbeek MM; Notting EA; Faas B; Claessens-Linskens R; Jongen PJ
    Acta Neurol Scand; 2010 May; 121(5):309-14. PubMed ID: 19925532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy.
    Elovaara I; Ukkonen M; Leppäkynnäs M; Lehtimäki T; Luomala M; Peltola J; Dastidar P
    Arch Neurol; 2000 Apr; 57(4):546-51. PubMed ID: 10768630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomic pattern analysis discriminates among multiple sclerosis-related disorders.
    Komori M; Matsuyama Y; Nirasawa T; Thiele H; Becker M; Alexandrov T; Saida T; Tanaka M; Matsuo H; Tomimoto H; Takahashi R; Tashiro K; Ikegawa M; Kondo T
    Ann Neurol; 2012 May; 71(5):614-23. PubMed ID: 22522477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CSF Levels of CXCL12 and Osteopontin as Early Markers of Primary Progressive Multiple Sclerosis.
    Marastoni D; Magliozzi R; Bolzan A; Pisani AI; Rossi S; Crescenzo F; Montemezzi S; Pizzini FB; Calabrese M
    Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34588298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.
    Öhrfelt A; Axelsson M; Malmeström C; Novakova L; Heslegrave A; Blennow K; Lycke J; Zetterberg H
    Mult Scler; 2016 Oct; 22(12):1587-1595. PubMed ID: 26754805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A metabolic perspective on CSF-mediated neurodegeneration in multiple sclerosis.
    Wentling M; Lopez-Gomez C; Park HJ; Amatruda M; Ntranos A; Aramini J; Petracca M; Rusielewicz T; Chen E; Tolstikov V; Kiebish M; Fossati V; Inglese M; Quinzii CM; Katz Sand I; Casaccia P
    Brain; 2019 Sep; 142(9):2756-2774. PubMed ID: 31305892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid concentration of Galectin-9 is increased in secondary progressive multiple sclerosis.
    Burman J; Svenningsson A
    J Neuroimmunol; 2016 Mar; 292():40-4. PubMed ID: 26943957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.
    Stilund M; Gjelstrup MC; Petersen T; Møller HJ; Rasmussen PV; Christensen T
    PLoS One; 2015; 10(4):e0119681. PubMed ID: 25860354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive multiple sclerosis cerebrospinal fluid induces inflammatory demyelination, axonal loss, and astrogliosis in mice.
    Cristofanilli M; Rosenthal H; Cymring B; Gratch D; Pagano B; Xie B; Sadiq SA
    Exp Neurol; 2014 Nov; 261():620-32. PubMed ID: 25111532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression.
    Lourenco P; Shirani A; Saeedi J; Oger J; Schreiber WE; Tremlett H
    Mult Scler; 2013 Apr; 19(5):577-84. PubMed ID: 22961214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary progressive multiple sclerosis diagnostic criteria: a reappraisal.
    Montalban X; Sastre-Garriga J; Filippi M; Khaleeli Z; Téllez N; Vellinga MM; Tur C; Brochet B; Barkhof F; Rovaris M; Miller DH; Polman CH; Rovira A; Thompson AJ
    Mult Scler; 2009 Dec; 15(12):1459-65. PubMed ID: 19995843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers.
    Ottervald J; Franzén B; Nilsson K; Andersson LI; Khademi M; Eriksson B; Kjellström S; Marko-Varga G; Végvári A; Harris RA; Laurell T; Miliotis T; Matusevicius D; Salter H; Ferm M; Olsson T
    J Proteomics; 2010 Apr; 73(6):1117-32. PubMed ID: 20093204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variability.
    Kiselev I; Bashinskaya V; Baulina N; Kozin M; Popova E; Boyko A; Favorova O; Kulakova O
    Mult Scler Relat Disord; 2019 Apr; 29():130-136. PubMed ID: 30711878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioenergetic Failure in Rat Oligodendrocyte Progenitor Cells Treated with Cerebrospinal Fluid Derived from Multiple Sclerosis Patients.
    Mathur D; Riffo-Campos AL; Castillo J; Haines JD; Vidaurre OG; Zhang F; Coret-Ferrer F; Casaccia P; Casanova B; Lopez-Rodas G
    Front Cell Neurosci; 2017; 11():209. PubMed ID: 28775680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of cerebrospinal fluid levels of lateral olfactory tract usher substance (LOTUS) with disease activity in multiple sclerosis.
    Takahashi K; Kurihara Y; Suzuki Y; Goshima Y; Tanaka F; Takei K
    JAMA Neurol; 2015 Feb; 72(2):176-9. PubMed ID: 25437093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.